Results for tag: "Spinocerebellar Ataxia Drug"

Spinocerebellar Ataxia (SCA) is a rare, inherited neurological disorder that affects the cerebellum, a part of the brain that controls coordination and balance. As a result, people with SCA experience difficulty with movement, speech, and coordination. Treatment for SCA is limited and there is no cure. However, drugs are available to help manage symptoms and slow the progression of the disease. The SCA drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including SCA. These drugs are typically prescribed by neurologists and other healthcare professionals. The SCA drug market is expected to grow in the coming years due to the increasing prevalence of SCA and the development of new treatments. Some companies in the SCA drug market include AbbVie, Biogen, and Novartis. These companies are involved in the research and development of new treatments for SCA, as well as the marketing and distribution of existing treatments. Show Less Read more